Argenx Nears Phase III In Myasthenia Gravis

 
• By John Davis
  
Acetylcholine
Antibodies against acetylcholine receptors in neuromuscular junctions are a cause of myasthenia gravis • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D